

ORGANIZING COMMITTEE

Harold A. Harvey
Allan Lipton
Richard J. Santen

PROGRAM

List of Speakers 3267s

Introduction to the Conference, *Aromatase: New Perspectives for Breast Cancer.*
Richard J. Santen 3268s

Review of Studies on Estrogen Biosynthesis in the Human.
Pentti K. Siiteri 3269s

Physiology, Biochemistry, and Biological Significance

Chairpersons: Pentti K. Siiteri
Richard J. Santen

Aromatase in the Central Nervous System.
F. Naftolin and Neil J. MacLusky 3274s

Biochemical Mechanism of Aromatization.
Jack Fishman 3277s

Discussion 3279s

Epidemiological Considerations: Aromatase, Obesity, and Breast Carcinoma

Chairpersons: Marvin A. Kirschner
Kenneth J. Ryan

Obesity, Androgens, Estrogens, and Cancer Risk.
M. A. Kirschner, G. Schneider, N.H. Ertel, and E. Worton 3281s

Cyclic Ovarian Function and Breast Cancer.
Barry M. Sherman, Robert B. Wallace, and Judy A. Bean 3286s

Relationship of Obesity to Blood Estrogens.
Barnett Zumoff 3289s

Discussion 3292s

In Vitro and in Vivo Assay Methodology and Biochemistry

Chairpersons: Pentti K. Siiteri
Kenneth J. Ryan

In Vitro Assays of Aromatase and Their Role in Studies of Estrogen Formation in Target Tissues.
Judith Weisz 3295s

Multiple Forms of Aromatase and Response of Breast Cancer Aromatase to Antiplacental Aromatase II Antibodies.
Yoshio Osawa, Buichi Tochigi, Tadayoshi Higashiyama, Carol Yarborough, Tohoru Nakamura, and Takara Yamamoto 3299s

Discussion 3305s

Pharmacological Inhibitors of Aromatase: Biochemical Studies

Chairpersons: Harry Brodie
Pentti K. Siiteri

Methods and Results of Aromatization Studies <i>in Vivo</i> . <i>Christopher Longcope</i>	3307s
Overview of Recent Development of Aromatase Inhibitors. <i>Angela M. H. Brodie</i>	3312s
Basic Studies on Aminoglutethimide. <i>Hilton A. Salhanick</i>	3315s
Design of Mechanism-based Inactivators of Human Placental Aromatase. <i>Patrick A. Marcotte and Cecil H. Robinson</i>	3322s
A New Hypothesis Based on Suicide Substrate Inhibitor Studies for the Mechanism of Action of Aromatase. <i>Douglas F. Covey and William F. Hood</i>	3327s
Discussion	3332s
Substituted C ₁₉ Steroid Analogs as Inhibitors of Aromatase. <i>Robert W. Brueggemeier, Catherine E. Snider, and Raymond E. Counsell</i>	3334s
Estrogen Synthesis in Human Breast Tumor and Its Inhibition by Testololactone and Bromoandrostenedione. <i>Thomas L. Dao</i>	3338s
Biochemistry of Aromatase: Significance to Female Reproductive Physiology. <i>Kenneth J. Ryan</i>	3342s

Pharmacological Inhibitors of Aromatase: *In Vivo* Studies

Chairpersons: Christopher Longcope
Richard J. Santen

<i>In Vivo</i> Effects of Δ^1 -Testololactone on Peripheral Aromatization. <i>Howard L. Judd, Robert M. Barone, Larry R. Laufer, Joseph C. Gambone, Steven L. Monfort, and Bill L. Lasley</i>	3345s
Steroid Hormone Profiles in Women Treated with Aminoglutethimide for Metastatic Carcinoma of the Breast. <i>E. Samojlik, R. J. Santen, M. A. Kirschner, and N. H. Ertel</i>	3349s
<i>In Vivo</i> and <i>in Vitro</i> Pharmacological Studies of Aminoglutethimide as an Aromatase Inhibitor. <i>R. J. Santen, S. J. Santner, N. Tilsen-Mallett, H. R. Rosen, E. Samojlik, and J. D. Veldhuis</i>	3353s
Discussion	3357s

Aromatase Inhibitors as Treatment of Animal Breast Carcinoma Models

Chairperson: Richard J. Santen

Effects of Aromatase Inhibitor 4-Hydroxyandrostenedione and Other Compounds in the 7,12-Dimethylbenz(a)anthracene-induced Breast Carcinoma Model. <i>Angela M. H. Brodie, Wesley M. Garrett, James R. Hendrickson, and Chon-Hwa Tsai-Morris</i>	3360s
Discussion	3363s

Aromatase in Human Breast Carcinoma—Biochemistry: *In Vitro* Inhibitors

Chairpersons: Angela M. H. Brodie
William R. Miller

Significance of Aromatase Activity in Human Breast Cancer. <i>W. R. Miller, R. A. Hawkins, and A. P. M. Forrest</i>	3365s
Aromatase in Human Breast Carcinoma. <i>E. Perel, M. E. Blackstein, and D. W. Killinger</i>	3369s
Comparative Studies of Aromatase Inhibitors in Relation to the Significance of Estrogen Synthesis in Human Mammary Tumors. <i>Yusuf J. Abul-Hajj</i>	3373s
Comparative Studies of Aromatase Inhibitors in Cultured Human Breast Cancer Cells. <i>J. H. MacIndoe, G. R. Woods, L. A. Etre, and D. F. Covey</i>	3378s
A Reassessment of the Role of Breast Tumor Aromatization. <i>H. Leon Bradlow</i>	3382s
Discussion	3385s

Aromatase Inhibitors as Treatment of Human Breast Carcinoma

Chairpersons: Allan Lipton
Trevor J. Powles

Δ^1 -Testololactone: Clinical Trials. <i>Albert Segaloff</i>	3387s
Treatment of Advanced Breast Cancer with Aminoglutethimide: A 14-Year Experience. <i>Kenneth E. Gale</i>	3389s
Adequacy of Estrogen Suppression with Aminoglutethimide and Hydrocortisone as Treatment of Human Breast Cancer: Correlation of Hormonal Data with Clinical Responses. <i>Richard J. Santen, Thomas J. Worgul, Eugeniusz Samojlik, Alice E. Boucher, Allan Lipton, and Harold Harvey</i>	3397s
Aminoglutethimide in the Treatment of Metastatic Breast Cancer. <i>Michael B. Troner</i>	3402s
Aminoglutethimide in the Treatment of Advanced Postmenopausal Breast Cancer. <i>Adrian L. Harris, Trevor J. Powles, and Ian E. Smith</i>	3405s
Tamoxifen and Aminoglutethimide in Advanced Breast Cancer. <i>Joseph Corkery, Robert C. F. Leonard, I. Craig Henderson, Rebecca S. Gelman, Joseph Hourihan, Diane M. Ascoli, and Hilton A. Salhanick</i>	3409s
Adjuvant Aminoglutethimide Therapy for Postmenopausal Patients with Primary Breast Cancer: Progress Report. <i>R. Charles Coombes, Clair Chilvers, Mitch Dowsett, Jean-Claude Gazet, Hubert T. Ford, Radka Bettelheim, Caroline Gordon, Ian E. Smith, David Zava, Trevor J. Powles, and Investigators of the Collaborative Breast Cancer Project</i>	3415s
Discussion	3418s

Antiestrogens as Alternative Means of Inhibiting Estrogen Action

Chairpersons: Allan Lipton
William L. McGuire

New Strategies for Investigating Antiestrogen Action in Breast Cancer. <i>William Leo McGuire</i>	3420s
Discussion	3422s
Antiestrogen Treatment of Breast Cancer: An Overview. <i>Olof H. Pearson, Andrea Manni, and Baha'uddin M. Arafah</i>	3424s
Discussion	3428s

Randomized Trials of Aromatase Inhibitors versus Antiestrogens

Chairpersons: William L. McGuire
Harold A. Harvey

Tamoxifen versus Aminoglutethimide versus Combined Tamoxifen and Aminoglutethimide in the Treatment of Advanced Breast Carcinoma. <i>Ian E. Smith, Adrian L. Harris, Michael Morgan, Jean-Claude Gazet, and J. Alan McKinna</i>	3430s
Discussion	3433s
Randomized Trial of Aminoglutethimide versus Tamoxifen in Metastatic Breast Cancer. <i>Allan Lipton, Harold A. Harvey, Richard J. Santen, Alice Boucher, Deborah White, Albert Bernath, Richard Dixon, George Richards, and Ahmed Shafik</i>	3434s
Aminoglutethimide in Tamoxifen-resistant Patients: The Melbourne Experience. <i>Robin M. L. Murray and Paula Pitt</i>	3437s
Discussion	3439s
Phase II Study of Aminoglutethimide and Medroxyprogesterone Acetate in the Treatment of Patients with Advanced Breast Cancer. <i>Gerd A. Nagel, Hans-Erik Wander, and Hans-Christian Blossey</i>	3442s
Discussion	3444s

Aminoglutethimide in Tamoxifen-resistant Patients

Chairpersons: Harold A. Harvey
William L. McGuire

- Use of Aminoglutethimide as Second-Line Endocrine Therapy in Metastatic Breast Cancer.
Stanley B. Kaye, Robert L. Woods, Richard M. Fox, Alan S. Coates, and Martin H. N. Tattersall 3445s
- Aminoglutethimide after Tamoxifen Therapy in Advanced Breast Cancer: M. D. Anderson Hospital Experience.
Aman U. Buzdar, Kimberly C. Powell, and George R. Blumenschein 3448s

Aromatase Inhibition versus Surgical Ablation

Chairpersons: Harold A. Harvey
William L. McGuire

- Cross-Over Comparison of Tamoxifen and Aminoglutethimide in Advanced Breast Cancer.
Harold A. Harvey, Allan Lipton, Deborah S. White, Richard J. Santen, Alice E. Boucher, Ahmed S. Shafik, Richard J. Dixon, and Members of The Central Pennsylvania Oncology Group 3451s
- Comparison of Surgical Adrenalectomy to Medical Adrenalectomy in Patients with Metastatic Carcinoma of the Breast.
Samuel A. Wells, Jr., Thomas J. Worgul, Eugeniusz Samojlik, Alice E. Boucher, Allan Lipton, Harold Harvey, Deborah White, Emma Smart, Charles Cox, and Richard J. Santen 3454s

Combinations of Agents to Inhibit Estrogenic Actions as Treatment of Breast Carcinoma

Chairpersons: William L. McGuire
Harold A. Harvey

- Clinical Trial of Multiple Endocrine Therapy for Metastatic and Locally Advanced Breast Cancer with Tamoxifen-Aminoglutethimide-Danazol Compared to Tamoxifen Used Alone.
Trevor J. Powles, C. Gordon, and R. C. Coombes 3458s
- Progress Report on Two Clinical Trials in Women with Advanced Breast Cancer. Trial I: Tamoxifen versus Tamoxifen plus Aminoglutethimide; Trial II: Aminoglutethimide in Patients with Prior Tamoxifen Exposure.
James N. Ingle, Stephanie J. Green, David L. Ahmann, John H. Edmonson, William C. Nichols, Stephen Frytak, and Joseph Rubin 3461s
- Discussion 3464s
- Closing Remarks to the Conference, *Aromatase: New Perspectives for Breast Cancer*.
Allan Lipton, Harold A. Harvey, and Richard J. Santen 3468s

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

42 (8 Supplement)

Cancer Res 1982;42:3334s-3450s.

Updated version Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/42/8_Supplement.citation

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/42/8_Supplement.citation. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.